APO RESEARCH · REPORT
Peptide CXO
Peptide CXO covers outsourced research, process development and manufacturing for peptide programmes, from research material and analytical work to clinical and commercial supply.
Selected research
Industry Research
Peptide CXO Industry Research Report 2026
Market perspective
The global Peptide CXO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Peptide CXO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Peptide CXO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Peptide CXO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Peptide CXO include Chinese Peptide Company, WuXi AppTec, Shenzhen JYMed Technology, ReaLi Tide Biological Technology, Jiangsu Sinopep-Allsino Biopharmaceutical, LONZA, Asymchem, GL Biochem and Chengdu Shengnuo Biotechnology, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Peptide CXO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Peptide CXO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide CXO Market by Company
Chinese Peptide Company
WuXi AppTec
Shenzhen JYMed Technology
ReaLi Tide Biological Technology
Jiangsu Sinopep-Allsino Biopharmaceutical
LONZA
Asymchem
GL Biochem
Chengdu Shengnuo Biotechnology
AmbioPharm
Polypeptide
Pepscan
JPT Peptide
Bicycle
Bachem
Peptide CXO Segment by Type
CRO
CMO/CDMO
Peptide CXO Segment by Application
Pharmaceutical Companies
Biotech Companies and Research Institutions
Peptide CXO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CXO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CXO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CXO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide CXO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CRO
- CMO/CDMO
Applications
- Pharmaceutical Companies
- Biotech Companies and Research Institutions
Companies covered
- Chinese Peptide Company
- WuXi AppTec
- Shenzhen JYMed Technology
- ReaLi Tide Biological Technology
- Jiangsu Sinopep-Allsino Biopharmaceutical
- LONZA
- Asymchem
- GL Biochem
- Chengdu Shengnuo Biotechnology
- AmbioPharm
- Polypeptide
- Pepscan
- JPT Peptide
- Bicycle
- Bachem
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Peptide CXO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CRO
- 2.2.3 CMO/CDMO
- 2.3 Peptide CXO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Biotech Companies and Research Institutions
- 2.4 Assumptions and Limitations
3 Peptide CXO Breakdown Data by Type
- 3.1 Global Peptide CXO Historic Market Size by Type (2021-2026)
- 3.2 Global Peptide CXO Forecasted Market Size by Type (2027-2032)
4 Peptide CXO Breakdown Data by Application
- 4.1 Global Peptide CXO Historic Market Size by Application (2021-2026)
- 4.2 Global Peptide CXO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Peptide CXO Market Perspective (2021-2032)
- 5.2 Global Peptide CXO Growth Trends by Region
- 5.2.1 Global Peptide CXO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Peptide CXO Historic Market Size by Region (2021-2026)
- 5.2.3 Peptide CXO Forecasted Market Size by Region (2027-2032)
- 5.3 Peptide CXO Market Dynamics
- 5.3.1 Peptide CXO Industry Trends
- 5.3.2 Peptide CXO Market Drivers
- 5.3.3 Peptide CXO Market Challenges
- 5.3.4 Peptide CXO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Peptide CXO Players by Revenue
- 6.1.1 Global Top Peptide CXO Players by Revenue (2021-2026)
- 6.1.2 Global Peptide CXO Revenue Market Share by Players (2021-2026)
- 6.2 Global Peptide CXO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Peptide CXO Head Office and Area Served
- 6.4 Global Peptide CXO Players, Product Type & Application
- 6.5 Global Peptide CXO Manufacturers Established Date
- 6.6 Global Peptide CXO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Peptide CXO Market Size (2021-2032)
- 7.2 North America Peptide CXO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Peptide CXO Market Size by Country (2021-2026)
- 7.4 North America Peptide CXO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Peptide CXO Market Size (2021-2032)
- 8.2 Europe Peptide CXO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Peptide CXO Market Size by Country (2021-2026)
- 8.4 Europe Peptide CXO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide CXO Market Size (2021-2032)
- 9.2 Asia-Pacific Peptide CXO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Peptide CXO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Peptide CXO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Peptide CXO Market Size (2021-2032)
- 10.2 South America Peptide CXO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Peptide CXO Market Size by Country (2021-2026)
- 10.4 South America Peptide CXO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide CXO Market Size (2021-2032)
- 11.2 Middle East & Africa Peptide CXO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Peptide CXO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Peptide CXO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chinese Peptide Company
- 12.1.1 Chinese Peptide Company Company Information
- 12.1.2 Chinese Peptide Company Business Overview
- 12.1.3 Chinese Peptide Company Revenue in Peptide CXO Business (2021-2026)
- 12.1.4 Chinese Peptide Company Peptide CXO Product Portfolio
- 12.1.5 Chinese Peptide Company Recent Developments
- 12.2 WuXi AppTec
- 12.2.1 WuXi AppTec Company Information
- 12.2.2 WuXi AppTec Business Overview
- 12.2.3 WuXi AppTec Revenue in Peptide CXO Business (2021-2026)
- 12.2.4 WuXi AppTec Peptide CXO Product Portfolio
- 12.2.5 WuXi AppTec Recent Developments
- 12.3 Shenzhen JYMed Technology
- 12.3.1 Shenzhen JYMed Technology Company Information
- 12.3.2 Shenzhen JYMed Technology Business Overview
- 12.3.3 Shenzhen JYMed Technology Revenue in Peptide CXO Business (2021-2026)
- 12.3.4 Shenzhen JYMed Technology Peptide CXO Product Portfolio
- 12.3.5 Shenzhen JYMed Technology Recent Developments
- 12.4 ReaLi Tide Biological Technology
- 12.4.1 ReaLi Tide Biological Technology Company Information
- 12.4.2 ReaLi Tide Biological Technology Business Overview
- 12.4.3 ReaLi Tide Biological Technology Revenue in Peptide CXO Business (2021-2026)
- 12.4.4 ReaLi Tide Biological Technology Peptide CXO Product Portfolio
- 12.4.5 ReaLi Tide Biological Technology Recent Developments
- 12.5 Jiangsu Sinopep-Allsino Biopharmaceutical
- 12.5.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
- 12.5.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
- 12.5.3 Jiangsu Sinopep-Allsino Biopharmaceutical Revenue in Peptide CXO Business (2021-2026)
- 12.5.4 Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Product Portfolio
- 12.5.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
- 12.6 LONZA
- 12.6.1 LONZA Company Information
- 12.6.2 LONZA Business Overview
- 12.6.3 LONZA Revenue in Peptide CXO Business (2021-2026)
- 12.6.4 LONZA Peptide CXO Product Portfolio
- 12.6.5 LONZA Recent Developments
- 12.7 Asymchem
- 12.7.1 Asymchem Company Information
- 12.7.2 Asymchem Business Overview
- 12.7.3 Asymchem Revenue in Peptide CXO Business (2021-2026)
- 12.7.4 Asymchem Peptide CXO Product Portfolio
- 12.7.5 Asymchem Recent Developments
- 12.8 GL Biochem
- 12.8.1 GL Biochem Company Information
- 12.8.2 GL Biochem Business Overview
- 12.8.3 GL Biochem Revenue in Peptide CXO Business (2021-2026)
- 12.8.4 GL Biochem Peptide CXO Product Portfolio
- 12.8.5 GL Biochem Recent Developments
- 12.9 Chengdu Shengnuo Biotechnology
- 12.9.1 Chengdu Shengnuo Biotechnology Company Information
- 12.9.2 Chengdu Shengnuo Biotechnology Business Overview
- 12.9.3 Chengdu Shengnuo Biotechnology Revenue in Peptide CXO Business (2021-2026)
- 12.9.4 Chengdu Shengnuo Biotechnology Peptide CXO Product Portfolio
- 12.9.5 Chengdu Shengnuo Biotechnology Recent Developments
- 12.10 AmbioPharm
- 12.10.1 AmbioPharm Company Information
- 12.10.2 AmbioPharm Business Overview
- 12.10.3 AmbioPharm Revenue in Peptide CXO Business (2021-2026)
- 12.10.4 AmbioPharm Peptide CXO Product Portfolio
- 12.10.5 AmbioPharm Recent Developments
- 12.11 Polypeptide
- 12.11.1 Polypeptide Company Information
- 12.11.2 Polypeptide Business Overview
- 12.11.3 Polypeptide Revenue in Peptide CXO Business (2021-2026)
- 12.11.4 Polypeptide Peptide CXO Product Portfolio
- 12.11.5 Polypeptide Recent Developments
- 12.12 Pepscan
- 12.12.1 Pepscan Company Information
- 12.12.2 Pepscan Business Overview
- 12.12.3 Pepscan Revenue in Peptide CXO Business (2021-2026)
- 12.12.4 Pepscan Peptide CXO Product Portfolio
- 12.12.5 Pepscan Recent Developments
- 12.13 JPT Peptide
- 12.13.1 JPT Peptide Company Information
- 12.13.2 JPT Peptide Business Overview
- 12.13.3 JPT Peptide Revenue in Peptide CXO Business (2021-2026)
- 12.13.4 JPT Peptide Peptide CXO Product Portfolio
- 12.13.5 JPT Peptide Recent Developments
- 12.14 Bicycle
- 12.14.1 Bicycle Company Information
- 12.14.2 Bicycle Business Overview
- 12.14.3 Bicycle Revenue in Peptide CXO Business (2021-2026)
- 12.14.4 Bicycle Peptide CXO Product Portfolio
- 12.14.5 Bicycle Recent Developments
- 12.15 Bachem
- 12.15.1 Bachem Company Information
- 12.15.2 Bachem Business Overview
- 12.15.3 Bachem Revenue in Peptide CXO Business (2021-2026)
- 12.15.4 Bachem Peptide CXO Product Portfolio
- 12.15.5 Bachem Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst